Study of a new way to select stem cells for transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a machine that picks out healthy stem cells for a bone marrow transplant. It may help people with certain blood cancers or disorders get a transplant with fewer complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer like leukemia, lymphoma, or myelodysplastic syndrome that is in remission or has come back once or twice.
- You have a donor who has passed a blood test showing they don't have antibodies against your cells within 28 days of starting treatment.
- You are not pregnant or breastfeeding.
- You do not have a known allergy to DMSO, a preservative used in stem cell storage.
- You are able to follow study instructions and have a caregiver to help you at home.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.